SNDX-62122 / Syndax Pharma - LARVOL DELTA

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event (Syndax Press Release) - "SNDX-62122 is in development for MF, with submission of an IND and initiation of a Phase 1 trial in MF expected in 2027. During the R&D Event, the Company will highlight recently published revumenib preclinical data showing that menin is a novel dependency in proliferative megakaryocytes, major drivers of MF. The Company expects the development of SNDX-62122 to be informed and de-risked by a Phase 1/2 proof-of-principle trial of revumenib in MF that is expected to initiate in the fourth quarter of 2026 with initial clinical data expected in the second half of 2027...During the R&D event, the Company will highlight its late-stage revumenib..."

Clinical • IND • New P1 trial • New P1/2 trial • P1/2 data • Preclinical • Myelofibrosis